Galena Biopharma (SLS)
(Delayed Data from NSDQ)
$1.14 USD
+0.02 (1.79%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1.14 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SLS 1.14 +0.02(1.79%)
Will SLS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SLS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLS
Galena Biopharma (SLS) Upgraded to Buy: Here's What You Should Know
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
SLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galena Biopharma, Inc. (SLS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Other News for SLS
Solstice Minerals Director Increases Shareholding
Solaris Reports 11,570 g/t Silver and 12.3 g/t Gold in First Assays From Sampling Epithermal Mineralization Discovered As Part of Warintza Regional Exploration Program
Solaris Unveils High-Grade Silver and Gold Assays
Solaris Announces Results of Annual General Meeting of Shareholders
SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia